Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Cert. of designation
Quarterly results
Director departure
9 METERS BIOPHARMA, INC. (INNT) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/18/2023 8-K Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direc...
Docs: "WITNESSETH : WHEREAS, the Parties entered into that certain Forbearance Agreement, dated as of April 26, 2023, as amended by that certain Amendment No. 1 to Forbearance Agreement, dated as of May 18, 2023 ; WHEREAS, the Forbearance Period expired on or about May 29, 2023; WHEREAS, the Note Parties have requested that Purchaser continue to forbear from enforcing rights or remedies related to the Existing Defaults and that the Note be amended as set forth herein, and Purchaser has agreed to the foregoing, in each case upon the terms and subject to the conditions set forth herein; NOW, THEREFORE, in consideration of the foregoing premises, and other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: AGREEME..."
06/16/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/19/2023 8-K Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an...
Docs: "AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT"
05/15/2023 8-K Quarterly results
Docs: "9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023"
04/27/2023 8-K Quarterly results
04/06/2023 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
04/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding its GIP Antagonist NM-136 for Obesity RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. , a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration on the request for a Type B pre-IND meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136 in the U.S. Completion of this i..."
03/28/2023 8-K Quarterly results
03/15/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "COMMON STOCK PURCHASE WARRANT 9 METERS BIOPHARMA, INC.",
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT 9 METERS BIOPHARMA, INC.",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT 9 METERS BIOPHARMA, INC.",
"4101 Lake Boone Trail, Suite 300, Raleigh, NC 27607 PO Drawer 17803, Raleigh, NC 27619",
"SECURITIES PURCHASE AGREEMENT",
"9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules",
"9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules"
03/13/2023 8-K Other Events  Interactive Data
Docs: "C L IN IC AL STAG E C O M PANY P IO NE E R ING NOVE L T R E AT M E NT S FO R PE O PL E W IT H R AR E O R D E B IL ITAT ING D IG E ST IVE D IS E AS E S"
03/13/2023 8-K Other Events  Interactive Data
01/13/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "FIRST AMENDMENT TO AMENDED AND RESTATED SENIOR SECURED CONVERTIBLE NOTE DUE 2025"
11/29/2022 8-K Quarterly results
11/08/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022"
11/01/2022 8-K Quarterly results
10/21/2022 8-K Quarterly results
10/17/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED",
"9 Meters Biopharma Announces 1-for-20 Reverse Stock Split"
10/06/2022 8-K Quarterly results
09/29/2022 8-K Quarterly results
09/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome",
"CLINICAL STAGE COMPANY P IONEERING NOVEL TREATMENTS FOR PEOPLE WITH RARE OR DEBIL ITAT ING DIGEST IVE D ISEASES"
08/15/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
04/13/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities  Interactive Data
03/23/2022 8-K Investor presentation
Docs: "9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021",
"FOCUSED ON RARE AND UNMET NEEDS IN DIGESTIVE DISEASES AND UNIQUE GI B IOLOGY"
02/28/2022 8-K Quarterly results
02/11/2022 8-K Quarterly results
01/24/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors"
01/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Reimbursement of Relocation Expenses.",
"SEPARATION AND CONSULTING AGREEMENT",
"9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer"
01/03/2022 8-K Other Events  Interactive Data
Docs: "9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy